Scientists have developed a test that uses cells from a single donor’s blood to predict whether a new drug will cause a severe reaction in humans.
The test could avert disasters like the 2006 trial of the drug TGN1412, which led to six healthy young men being admitted to intensive care with multiple organ failure. The volunteers receiving TGN1412 experienced a catastrophic inflammatory reaction called a cytokine storm.
Cytokine storm reactions are a particular worry for new biological therapies, or “biologics”, which use biological material such as antibodies. Many blockbuster drugs such as the cancer drugs Herceptin and Avastin are biologics, as are around a third of medicines in the pharmaceutical pipeline. Because these medicines are specific to humans, they can cause severe reactions that don’t materialise in animal studies, so tests on human cells are essential.
However, cytokine storm side effects are hard to predict with tests were just one cell type is used, since they depend on interactions between blood cells and endothelial cells, which form the lining of blood vessels. But because endothelial cells are deep within the body, they are normally only grown from tissue removed in surgery or post mortem, or from umbilical vessels after birth.
Because of this, current tests use endothelial cells taken from vessels of one donor, and white blood cells from a different donor. When cells from two different donors are used, one may have an immune reaction to the other, meaning the system is already primed for inflammation before the drug is added. This can result in the test falsely showing a severe immune reaction to a drug that is safe.
Researchers at Imperial College London got around this problem by isolating stem cells from the blood of a volunteer, and using them to grow endothelial cells in a dish. They then took white blood cells which they added to the donor’s own endothelial cells to recreate the unique conditions found in their blood vessels. When TGN1412 was added to the test tube, the mixture of cells released a cytokine storm, as would happen inside the body.
The new method is better as it only requires blood from one donor and doesn’t mix cells from different people, with the advantage of making a more reliable test.
Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial College London, who led the study, said: “As biological therapies become more mainstream, it’s more likely that drugs being tested on humans for the first time will have unexpected and potentially catastrophic effects. We’ve used adult stem cell technology to develop a laboratory test that could prevent another disaster like the TGN1412 trial.
“Drug companies have the technical capacity to start using this test now, but we’re working on developing an off-the-shelf kit which will make it easy to use on a large scale.”
Dr Daniel Reed, the first author on the study, said: ”A further benefit of this new technology is that personalised therapies can be tested to see how safe and effective they will be for an individual.”
The Latest on: Personalised therapies
via Google News
The Latest on: Personalised therapies
- Personalised treatments have significant impact on back pain - studyon October 20, 2019 at 8:44 am
In the trial, patients with back pain received personalised treatment, known as cognitive functional therapy, according to their own needs. In some cases the emphasis was on physical factors such as ...
- This App Prevents Jet Lag By Giving You Personalized Instructionson October 20, 2019 at 6:09 am
Since the 1990s, NASA astronauts and mission controllers preparing for missions have used personalized light therapy plans to adjust their sleep-wake cycles in order to make sure they’re on the right ...
- Pioneering cell therapies for nonresponders to current immunotherapieson October 17, 2019 at 6:30 am
"While we did not expect to find killer T lymphocytes in the blood of these patients with cold tumors of low mutational burden, we have now shown that we can identify and select these cells in blood, ...
- RNA therapies explainedon October 16, 2019 at 8:55 am
RNA therapies that use mRNAs are being used to develop personalized cancer vaccines, as well as vaccines for infectious diseases such as Zika virus, which has been linked with the condition ...
- A systems approach to clinical oncology uses deep phenotyping to deliver personalized careon October 16, 2019 at 7:32 am
A systems biology-based approach would help to decipher this complexity, to deeply characterize the pathophysiology of the disease and to stratify cancers into appropriate molecular subtypes to ...
- IM Therapeutics Secures $10 Million In Funding To Develop Personalized Therapies For Autoimmune Diseaseson October 15, 2019 at 12:29 pm
IM Therapeutics, a clinical-stage company developing personalized therapies for autoimmune diseases, announced it raised $10 million in Series A funding IM Therapeutics — a clinical-stage company that ...
- Personalized Medicine Market: Facts, Figures and Analytical Insights 2019 - 2026on October 15, 2019 at 4:28 am
Personalized Medicine Market Outlook Growing dominance of various types of cancer, affordability of personalized medicine therapy in cancer drugs and various other disease indications are expected to ...
- Nexstim Plc Therapy Business Update Q3 2019on October 14, 2019 at 11:30 pm
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalised treatment of major depressive disorder (MDD) – ...
- NextUp: Tmunity Therapeutics Is Pioneering Personalized Cancer Treatmentson October 14, 2019 at 12:27 pm
The company is developing a diverse portfolio of new cancer treatments that aim to perfect the process of T-cell activation and direction in the body. Tmunity has 14 therapies in its pipeline in ...
- 3 Essential Capabilities to Develop Gene Therapieson October 14, 2019 at 6:38 am
1. Advanced manufacturing Unlike traditional medications, most gene therapies are personalized treatments designed for an individual patient or manufactured in small batches, the PwC report says.
via Bing News